According to Neurocrine Biosciences
's latest financial reports the company has $1.03 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $1.03 B | 4.28% |
2022-12-31 | $0.98 B | 39.08% |
2021-12-31 | $0.71 B | -11.2% |
2020-12-31 | $0.80 B | 19.46% |
2019-12-31 | $0.67 B | 3.01% |
2018-12-31 | $0.65 B | 26.16% |
2017-12-31 | $0.51 B | 67.86% |
2016-12-31 | $0.30 B | -18.95% |
2015-12-31 | $0.37 B | 95.65% |
2014-12-31 | $0.19 B | 32.98% |
2013-12-31 | $0.14 B | -15.76% |
2012-12-31 | $0.17 B | 34.01% |
2011-12-31 | $0.12 B | 1.76% |
2010-12-31 | $0.12 B | 137.29% |
2009-12-31 | $53.46 M | -33.56% |
2008-12-31 | $80.47 M | -55.14% |
2007-12-31 | $0.17 B | -1.76% |
2006-12-31 | $0.18 B | -33.13% |
2005-12-31 | $0.27 B | -9.32% |
2004-12-31 | $0.30 B | -33.55% |
2003-12-31 | $0.45 B | 85.19% |
2002-12-31 | $0.24 B | -23.52% |
2001-12-31 | $0.31 B |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Pfizer PFE | $12.69 B | 1,130.13% | ๐บ๐ธ USA |
AbbVie ABBV | $12.81 B | 1,142.34% | ๐บ๐ธ USA |
Eli Lilly LLY | $2.92 B | 183.80% | ๐บ๐ธ USA |
Repligen
RGEN | $0.75 B | -27.17% | ๐บ๐ธ USA |
Athersys ATHX | $1.02 M | -99.90% | ๐บ๐ธ USA |
ANI Pharmaceuticals ANIP | $0.22 B | -78.57% | ๐บ๐ธ USA |
Palatin Technologies PTN | $9.48 M | -99.08% | ๐บ๐ธ USA |
Royalty Pharma RPRX | $1.23 B | 19.60% | ๐ฌ๐ง UK |